Trefoil Therapeutics is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as regenerative pharmacologic therapies to treat serious corneal endothelial diseases and epithelial disorders. Its lead product candidate, TTHX1114, is an engineered form of FGF‑1 designed to reverse vision loss by stimulating cell proliferation and migration. The underlying technology was developed by co‑founder Michael Blaber, Ph.D., and is licensed from Florida State University. The company is led by co‑founder and CEO David Eveleth, Ph.D., and is advancing both intravitreal/clinical and topical programs. Trefoil plans to complete a Phase 2a proof‑of‑concept study in corneal endothelial dystrophy (including Fuchs dystrophy) and to file an IND with the FDA in early 2020 to initiate that clinical trial. The company is also conducting IND‑enabling studies for a topical formulation of TTHX1114 with a planned second IND submission for corneal epithelial conditions in 2021.

Total raised

$28M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2019